Loading...
XSHG603127
Market cap760mUSD
Jan 08, Last price  
15.92CNY
1D
-1.73%
1Q
-10.56%
IPO
505.32%
Name

Joinn Laboratories China Co Ltd

Chart & Performance

D1W1MN
XSHG:603127 chart
P/E
28.16
P/S
4.70
EPS
0.57
Div Yield, %
0.00%
Shrs. gr., 5y
3.81%
Rev. gr., 5y
42.20%
Revenues
2.38b
+4.78%
97,389,156143,828,848184,814,905206,605,666241,805,209301,278,957408,798,150639,379,3381,075,904,9341,516,680,0312,267,970,9792,376,486,797
Net income
397m
-63.04%
9,625,52822,288,28548,996,19649,173,91351,692,49376,446,395108,338,318178,372,735315,013,896557,459,6091,074,257,178396,992,565
CFO
623m
-35.86%
20,331,87760,907,38082,375,992106,225,419118,822,186120,006,161176,075,671148,092,126428,385,736685,655,427971,066,113622,875,138
Dividend
Jul 31, 20240.16 CNY/sh

Profile

Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics studies, and pharmacology and efficacy studies. The Clinical Trial and Related Services segment provides clinical CRO services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment designs, produces, breeds, and sells research models, non-human primates, and rodents. The company also offers investment management and cell-based assay (CBA) services. Joinn Laboratories(China)Co.,Ltd. was founded in 1995 and is headquartered in Beijing, China.
URL
https://www.joinnlabs.com/
IPO date
Aug 25, 2017
Employees
2,500
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
2,376,487
4.78%
2,267,971
49.54%
Cost of revenue
1,561,391
1,356,082
Unusual Expense (Income)
NOPBT
815,096
911,889
NOPBT Margin
34.30%
40.21%
Operating Taxes
115,398
166,802
Tax Rate
14.16%
18.29%
NOPAT
699,698
745,087
Net income
396,993
-63.04%
1,074,257
92.71%
Dividends
Dividend yield
Proceeds from repurchase of equity
(113,582)
BB yield
1.18%
Debt
Debt current
27,540
Long-term debt
83,849
117,055
Deferred revenue
74,487
80,676
Other long-term liabilities
1
1
Net debt
(5,079,705)
(3,439,494)
Cash flow
Cash from operating activities
622,875
971,066
CAPEX
Cash from investing activities
Cash from financing activities
(361,678)
FCF
513,132
(281,566)
Balance
Cash
4,769,756
3,325,318
Long term investments
393,798
258,770
Excess cash
5,044,730
3,470,690
Stockholders' equity
2,915,585
2,644,373
Invested Capital
5,481,868
5,651,908
ROIC
12.57%
13.06%
ROCE
9.52%
10.75%
EV
Common stock shares outstanding
749,043
537,129
Price
12.86
-54.94%
28.54
-51.54%
Market cap
9,632,688
-37.16%
15,329,650
-64.31%
EV
4,554,707
11,897,321
EBITDA
944,608
1,032,849
EV/EBITDA
4.82
11.52
Interest
3,440
3,582
Interest/NOPBT
0.42%
0.39%